According to the World Health Organization, obesity is a chronic, progressive disease that often requires long-term management because it can recur over time.
When treatment stops, appetite can return, food thoughts may come back, and weight regain can happen. In semaglutide trials, participants regained an average of about two-thirds of their previous weight loss within one year of stopping treatment.
That is one reason maintenance dosing is vital. But what is the lowest effective GLP-1 dose that keeps you healthy, stable, and able to afford treatment?
How often do you take GLP-1 for weight loss?
For Wegovy injection, treatment starts at 0.25 mg once weekly and increases gradually to the maintenance dose, which is usually 1.7 mg or 2.4 mg once weekly. There’s also a 7.2 mg once-weekly option for adults who tolerate 2.4 mg but need to lose more weight.
For Zepbound, treatment starts at 2.5 mg once weekly, then also increases gradually to the maintenance doses of 5 mg, 10 mg, or 15 mg once weekly. The dose is increased at 2.5 mg increments after every 4 weeks.
These dosing schedules have been carefully tested in clinical trials. Split dosing, microdosing, and other alternative dosing routines are different approaches. Some doctors may recommend them for certain patients, but there’s still limited research on how well they work.
Can you take semaglutide every other week?
A 2025 modeling study found that every-other-week dosing kept roughly 75% of predicted weight loss, while giving a larger dose every two weeks could potentially maintain nearly all of the benefit.
The study modeled semaglutide at maintenance doses of 1.7 mg and 2.4 mg.
For semaglutide 2.4 mg once weekly, the model predicted about 17% steady-state body weight reduction. When the same 2.4 mg dose was taken every 14 days, the model predicted about 12% body weight reduction.
That means the every-other-week schedule kept about 72% of the modeled weight loss while using half as many injections.
For semaglutide 1.7 mg, the model predicted that every-other-week dosing kept about 69% of the weight loss compared with weekly dosing.
The study also modeled a person moving from 1.7 mg weekly to 2.4 mg every other week. In that case, the model estimated about 82% of the original weight loss at about half the injection cost, assuming cost is tied to the number of injections rather than the dose size.
Can you take tirzepatide every other week?
The model predicted steady-state body weight reductions of about 17%, 21%, and 23% for tirzepatide doses of 5 mg, 10 mg, and 15 mg taken once weekly. When those same doses were taken every two weeks, the model predicted weight reductions of about 12%, 16%, and 18%.
In short, people were predicted to keep roughly 75% of the weight loss when switching from weekly dosing to every-other-week dosing.
The model also suggested that some higher-dose, less frequent tirzepatide schedules might produce results close to lower-dose weekly schedules. For example, 5 mg weekly was modeled as roughly similar to 10 mg every 14 days. The paper also noted that 10 mg weekly looked roughly similar to 15 mg every 10 days in the model.
Is dosing GLP-1 every other week still effective?
Taking your GLP-1 dose every other week may still be effective, but mainly as a maintenance approach after reaching your goal weight. If you are still early in treatment or actively trying to lose weight, dosing less often may reduce the medication’s effect and make it harder to reach your goal.
A case series found that some adults who had already lost weight on weekly semaglutide or tirzepatide were able to maintain their results after switching to reduced-frequency dosing, usually every other week. In fact, their average weight dropped a little more during maintenance, from 74.1 kg to 72.4 kg, about 1.7 kg or 3.7 lb of additional average weight loss.
These patients had already reached a weight plateau before changing their schedule. Over an average of about 36 weeks, they maintained their weight loss, preserved metabolic improvements, and had stable skeletal muscle mass.
Do GLP-1s wear off by the end of the week?
Many injectable GLP-1 medications are designed to last for days. After a shot, the drug level rises, then slowly falls. If the next shot comes later than usual, there may still be some medication in the body, just less than there would be on a weekly schedule.
Semaglutide has a longer half-life of about 1 week and reaches steady levels after roughly 4 to 5 weeks of weekly dosing. Tirzepatide has a half-life of about 5 days, which also supports once-weekly dosing.
Weekly vs Every-Other-Week GLP-1 Chart
This visual shows how GLP-1 medication levels may rise and fall when the same dose is taken once weekly compared with every other week. It is a simplified educational model based on drug half-life.
GLP-1 maintenance dosing after weight loss
Here are some of the personal experiences shared on Reddit threads about Ozempic, Wegovy, Mounjaro, and Zepbound maintenance.
These stories line up with the study’s general idea that some people may maintain benefits with less medication. But they also show that there is no one-size plan. Some people do well with spacing. Some need weekly treatment. Some need dose changes over time.
- Some users report taking shots every 10 days or every 14 days for maintenance. For example, one Wegovy user said they moved to 1.7 mg every 14 days after first trying 10 to 12 days, with more hunger but a manageable appetite.
Comment
byu/HulaHulaCreations from discussion
inWegovyWeightLoss
- Cost comes up often. In one Wegovy discussion, a commenter noted that dosing every 14 days can make treatment much cheaper for people paying out of pocket.
Comment
byu/Auraluka from discussion
inWegovyWeightLoss
- Some tirzepatide users describe maintenance schedules such as 7.5 mg every 10 days or 5 mg every 10 days. One Mounjaro user said 7.5 mg every 10 days was working for maintenance, while another said 5 mg every 10 days worked for several months before they needed to adjust.
Comment
byu/AnyMathGirl from discussion
inMounjaro
- Some people report lower doses rather than longer spacing. One Ozempic user said they lost 105 pounds and maintained on 0.25 mg after previously using 1 mg.
Comment
byu/jasminee2020 from discussion
inOzempic
Benefits of alternative GLP-1 dosing
Possible risks and unknowns of alternative GLP-1 dosing
Who should be extra careful?
How to talk to your doctor about GLP-1 maintenance dose
If you are interested in alternative dosing, bring it up directly. You can ask questions such as these.
-
- Am I a good candidate for a lower maintenance dose?
-
- Would spacing my dose be safer than stopping completely?
-
- How should I track weight, appetite, side effects, and blood sugar?
-
- What symptoms should make me call you right away?
-
- If my weight starts to rise, when should we adjust the plan?
-
- Does my insurance or pharmacy setup make one option more affordable?
It may help to track your weight trend, hunger level, protein intake, activity, side effects, and medication dates for a few weeks.
Bottom line
GLP-1 dosing may eventually become more personalized than the standard once-weekly schedule, especially for maintenance. But for now, alternative regimens should be treated as a doctor-guided strategy, and not a do-it-yourself hack.
Alternative dosing may be more relevant after a person has already reached a stable dose, knows how they respond, and is discussing long-term maintenance with a clinician.
For new patients, ask how long treatment may last, what maintenance might look like, what happens if insurance stops covering it, and what lifestyle habits will support results.
Frequently Asked Questions
Articles you may also be interested in
Sources
Cengiz A, Wu CC, Lawley SD. Alternative dosing regimens of GLP-1 receptor agonists may reduce costs and maintain weight loss efficacy. Diabetes Obes Metab. 2025 Apr;27(4):2251-2258. doi: 10.1111/dom.16229. Epub 2025 Feb 14. PMID: 39950222; PMCID: PMC11885104.
Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, McGowan BM, Oral TK, Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF; STEP 1 Study Group. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022 Aug;24(8):1553-1564. doi: 10.1111/dom.14725. Epub 2022 May 19. PMID: 35441470; PMCID: PMC9542252.
Gleason, P. P., Urick, B. Y., Marshall, L. Z., Friedlander, N., Qiu, Y., & Leslie, R. S. (2024). Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes. Journal of Managed Care & Specialty Pharmacy, 30(8), 860–867. https://doi.org/10.18553/jmcp.2024.23332
Wong, M., Wu, A., Garhe, P. K., & Biermann, M. (2026). Reduced?Frequency GLP1 therapy maintains weight, body composition, and metabolic syndrome improvements: a case series. Obesity, 34(S1), 112–120. https://doi.org/10.1002/oby.70137




